+Follow
谢俊钦
No personal profile
51
Follow
6
Followers
0
Topic
0
Badge
Posts
Hot
谢俊钦
2021-07-23
never ever
Is It Too Late to Buy Moderna Stock?
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3544437345941731","uuid":"3544437345941731","gmtCreate":1581343323685,"gmtModify":1581393491157,"name":"谢俊钦","pinyin":"xjqxiejunqin","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/649e4596d1aafe577148310d6a5c4226","hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","hatId":"ca_profile_frame_5b7Fd6","hatName":"","vip":1,"status":2,"fanSize":6,"headSize":51,"tweetSize":25,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":9,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.54%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.06.28","exceedPercentage":"60.95%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.01.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"cbe1c45c584340f3bd9ae6c77e0e9981-1","templateUuid":"cbe1c45c584340f3bd9ae6c77e0e9981","name":"Academy Experiencer","description":"5 lessons learned","bigImgUrl":"https://community-static.tradeup.com/news/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://community-static.tradeup.com/news/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":6,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":7,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":174089117,"gmtCreate":1627052531439,"gmtModify":1703483463780,"author":{"id":"3544437345941731","authorId":"3544437345941731","name":"谢俊钦","avatar":"https://static.tigerbbs.com/649e4596d1aafe577148310d6a5c4226","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3544437345941731","authorIdStr":"3544437345941731"},"themes":[],"htmlText":"never ever","listText":"never ever","text":"never ever","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/174089117","repostId":"2153983451","repostType":2,"repost":{"id":"2153983451","pubTimestamp":1627045260,"share":"https://ttm.financial/m/news/2153983451?lang=&edition=fundamental","pubTime":"2021-07-23 21:01","market":"us","language":"en","title":"Is It Too Late to Buy Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2153983451","media":"Motley Fool","summary":"Past performance isn't necessarily indicative of future success -- but in this case it might just be.","content":"<p>If you had invested $100,000 in <b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> in early 2020, you would have well over $1,500,000 today, as shares of the biotech have skyrocketed thanks to its successful development of a vaccine for COVID-19. Any investor would be proud of such returns, particularly given the relatively short period it took the vaccine maker to accomplish this feat.</p>\n<p>But that raises an interesting question: After crushing the broader market over the past year and a half, how much upside does Moderna have left? Is it too late to get in on this high-flying biotech? Let's look into Moderna's prospects, both within the coronavirus market and beyond, to determine whether it is still worth purchasing its shares.</p>\n<p><img src=\"https://static.tigerbbs.com/c956dab14bf4026173f313850104ad4c\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>^SPX data by YCharts</p>\n<h3>Is the coronavirus vaccine tailwind over?</h3>\n<p>According to the U.S. Centers for Disease Control and Prevention (CDC), as of July 21, 161.9 million people in the U.S. have been fully vaccinated against COVID-19. Many more have received vaccines elsewhere in the world. The two leaders in this space -- Moderna and <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> -- have both reported that their respective vaccines are still effective after six months.</p>\n<p>There is evidence that Moderna's vaccine, mRNA-1273, is also potent against newer variants of the SARS-CoV-2 virus that causes the disease, including the delta variant that is now responsible for over 80% of new cases in the U.S. One could conclude from these facts that Moderna won't benefit a whole lot more from mRNA-1273. After all, the company's shares have already skyrocketed, and with the number of vaccinated people rising, how much can the biotech continue to profit from its success in this market?</p>\n<p>However, there are good reasons to think Moderna's coronavirus vaccine-related tailwind isn't over. <a href=\"https://laohu8.com/S/FBNC\">First</a>, Moderna continues to seek (and earn) regulatory wins, both in the U.S. and abroad. Back in June, the company applied for an Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for its vaccine to be administered to adolescents between the ages of 12 and 18. Moderna submitted a similar application to regulatory authorities in Switzerland last month, and the company's vaccine recently earned an EUA in India.</p>\n<p><img src=\"https://static.tigerbbs.com/6745743754cc8a567a6c76661e415ed8\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<p>Second, the biotech continues to sign new supply deals for mRNA-1273. Moderna announced a supply agreement with the government of Argentina on June 12 for 20 million doses of mRNA-1273, while both the U.S. government and the European Commission have purchased millions of additional doses of the vaccine.</p>\n<p>Finally, and perhaps most importantly, it still isn't clear how long mRNA-1273 provides immunity. During Moderna's first-quarter earnings conference call, CEO Stéphane Bancel said: \"we believe booster shots will be needed as we believe that the virus is not going away. We also believe from the scientific standpoint, that the highest efficacy booster over time will be provided by multivalent variant-specific booster.\"</p>\n<p>Moderna started evaluating booster candidates for its vaccine earlier this year. Meanwhile, Pfizer's CEO Albert Bourla has said that he believes demand for COVID-19 vaccines could become seasonal, much like the demand for flu vaccines. Of course, none of this is set in stone. The CDC and the FDA released a joint statement on July 8 saying that vaccinated Americans do not need booster shots right now.</p>\n<p>That may be true at the moment, but data from Pfizer has already strongly suggested that a booster dose administered six months post-vaccination produces higher antibodies titers in patients. This is important -- while Pfizer's vaccine remains effective after six months, its efficacy does seem to decrease.</p>\n<p>And with new variants like delta emerging, there are good reasons to think that a booster dose will eventually be needed for vaccinated people. Given these factors, it seems highly likely that Moderna will continue to benefit from its coronavirus vaccine financially, and its shares could still experience significant upside as a result.</p>\n<h3>What else does Moderna have to offer?</h3>\n<p>Beyond COVID-19, Moderna's mRNA vaccine platform shows huge potential. The company's pipeline currently boasts more than a dozen programs, most of which are potential vaccines against various infectious illnesses. In early July, the biotech started a phase 1/2 clinical trial for mRNA-1010, an investigational flu vaccine.</p>\n<p>The company argues that despite the wide availability of approved vaccines for the flu, this disease continues to cause serious health problems, in part because current vaccines are only 40% to 60% effective. Moderna is also looking to develop combination vaccines -- that is, vaccines that can confer immunity against more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> disease.</p>\n<p>There is no doubt the long-term opportunity is there for the company. As Moderna argues, of the more than 80 viruses discovered in the past 40 years, only 4% have commercially available vaccines in the U.S. The company thinks its mRNA approach to vaccination could help it create a raft of effective vaccines against some of these viruses.</p>\n<h3>Not too late to get in</h3>\n<p>There are two important reasons why it's not too late to buy shares of Moderna. <a href=\"https://laohu8.com/S/FFBC\">First</a>, the company will continue to benefit from its COVID-19 vaccine. Second, the biotech's long-term thesis (supported by the success of mRNA-1273) is attractive. Moderna is currently trading at just 12.5 times forward earnings, which, in my view, is more than fair given the company's prospects. <a href=\"https://laohu8.com/S/ISBC\">Investors</a> looking for solid biotech stocks to buy need look no further than Moderna.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Too Late to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Too Late to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 21:01 GMT+8 <a href=https://www.fool.com/investing/2021/07/23/is-it-too-late-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you had invested $100,000 in Moderna, Inc. in early 2020, you would have well over $1,500,000 today, as shares of the biotech have skyrocketed thanks to its successful development of a vaccine for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/is-it-too-late-to-buy-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/07/23/is-it-too-late-to-buy-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153983451","content_text":"If you had invested $100,000 in Moderna, Inc. in early 2020, you would have well over $1,500,000 today, as shares of the biotech have skyrocketed thanks to its successful development of a vaccine for COVID-19. Any investor would be proud of such returns, particularly given the relatively short period it took the vaccine maker to accomplish this feat.\nBut that raises an interesting question: After crushing the broader market over the past year and a half, how much upside does Moderna have left? Is it too late to get in on this high-flying biotech? Let's look into Moderna's prospects, both within the coronavirus market and beyond, to determine whether it is still worth purchasing its shares.\n\n^SPX data by YCharts\nIs the coronavirus vaccine tailwind over?\nAccording to the U.S. Centers for Disease Control and Prevention (CDC), as of July 21, 161.9 million people in the U.S. have been fully vaccinated against COVID-19. Many more have received vaccines elsewhere in the world. The two leaders in this space -- Moderna and Pfizer -- have both reported that their respective vaccines are still effective after six months.\nThere is evidence that Moderna's vaccine, mRNA-1273, is also potent against newer variants of the SARS-CoV-2 virus that causes the disease, including the delta variant that is now responsible for over 80% of new cases in the U.S. One could conclude from these facts that Moderna won't benefit a whole lot more from mRNA-1273. After all, the company's shares have already skyrocketed, and with the number of vaccinated people rising, how much can the biotech continue to profit from its success in this market?\nHowever, there are good reasons to think Moderna's coronavirus vaccine-related tailwind isn't over. First, Moderna continues to seek (and earn) regulatory wins, both in the U.S. and abroad. Back in June, the company applied for an Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for its vaccine to be administered to adolescents between the ages of 12 and 18. Moderna submitted a similar application to regulatory authorities in Switzerland last month, and the company's vaccine recently earned an EUA in India.\n\nImage source: Getty Images.\nSecond, the biotech continues to sign new supply deals for mRNA-1273. Moderna announced a supply agreement with the government of Argentina on June 12 for 20 million doses of mRNA-1273, while both the U.S. government and the European Commission have purchased millions of additional doses of the vaccine.\nFinally, and perhaps most importantly, it still isn't clear how long mRNA-1273 provides immunity. During Moderna's first-quarter earnings conference call, CEO Stéphane Bancel said: \"we believe booster shots will be needed as we believe that the virus is not going away. We also believe from the scientific standpoint, that the highest efficacy booster over time will be provided by multivalent variant-specific booster.\"\nModerna started evaluating booster candidates for its vaccine earlier this year. Meanwhile, Pfizer's CEO Albert Bourla has said that he believes demand for COVID-19 vaccines could become seasonal, much like the demand for flu vaccines. Of course, none of this is set in stone. The CDC and the FDA released a joint statement on July 8 saying that vaccinated Americans do not need booster shots right now.\nThat may be true at the moment, but data from Pfizer has already strongly suggested that a booster dose administered six months post-vaccination produces higher antibodies titers in patients. This is important -- while Pfizer's vaccine remains effective after six months, its efficacy does seem to decrease.\nAnd with new variants like delta emerging, there are good reasons to think that a booster dose will eventually be needed for vaccinated people. Given these factors, it seems highly likely that Moderna will continue to benefit from its coronavirus vaccine financially, and its shares could still experience significant upside as a result.\nWhat else does Moderna have to offer?\nBeyond COVID-19, Moderna's mRNA vaccine platform shows huge potential. The company's pipeline currently boasts more than a dozen programs, most of which are potential vaccines against various infectious illnesses. In early July, the biotech started a phase 1/2 clinical trial for mRNA-1010, an investigational flu vaccine.\nThe company argues that despite the wide availability of approved vaccines for the flu, this disease continues to cause serious health problems, in part because current vaccines are only 40% to 60% effective. Moderna is also looking to develop combination vaccines -- that is, vaccines that can confer immunity against more than one disease.\nThere is no doubt the long-term opportunity is there for the company. As Moderna argues, of the more than 80 viruses discovered in the past 40 years, only 4% have commercially available vaccines in the U.S. The company thinks its mRNA approach to vaccination could help it create a raft of effective vaccines against some of these viruses.\nNot too late to get in\nThere are two important reasons why it's not too late to buy shares of Moderna. First, the company will continue to benefit from its COVID-19 vaccine. Second, the biotech's long-term thesis (supported by the success of mRNA-1273) is attractive. Moderna is currently trading at just 12.5 times forward earnings, which, in my view, is more than fair given the company's prospects. Investors looking for solid biotech stocks to buy need look no further than Moderna.","news_type":1},"isVote":1,"tweetType":1,"viewCount":243,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":174089117,"gmtCreate":1627052531439,"gmtModify":1703483463780,"author":{"id":"3544437345941731","authorId":"3544437345941731","name":"谢俊钦","avatar":"https://static.tigerbbs.com/649e4596d1aafe577148310d6a5c4226","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3544437345941731","idStr":"3544437345941731"},"themes":[],"htmlText":"never ever","listText":"never ever","text":"never ever","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/174089117","repostId":"2153983451","repostType":2,"repost":{"id":"2153983451","pubTimestamp":1627045260,"share":"https://ttm.financial/m/news/2153983451?lang=&edition=fundamental","pubTime":"2021-07-23 21:01","market":"us","language":"en","title":"Is It Too Late to Buy Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2153983451","media":"Motley Fool","summary":"Past performance isn't necessarily indicative of future success -- but in this case it might just be.","content":"<p>If you had invested $100,000 in <b><a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b> in early 2020, you would have well over $1,500,000 today, as shares of the biotech have skyrocketed thanks to its successful development of a vaccine for COVID-19. Any investor would be proud of such returns, particularly given the relatively short period it took the vaccine maker to accomplish this feat.</p>\n<p>But that raises an interesting question: After crushing the broader market over the past year and a half, how much upside does Moderna have left? Is it too late to get in on this high-flying biotech? Let's look into Moderna's prospects, both within the coronavirus market and beyond, to determine whether it is still worth purchasing its shares.</p>\n<p><img src=\"https://static.tigerbbs.com/c956dab14bf4026173f313850104ad4c\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>^SPX data by YCharts</p>\n<h3>Is the coronavirus vaccine tailwind over?</h3>\n<p>According to the U.S. Centers for Disease Control and Prevention (CDC), as of July 21, 161.9 million people in the U.S. have been fully vaccinated against COVID-19. Many more have received vaccines elsewhere in the world. The two leaders in this space -- Moderna and <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> -- have both reported that their respective vaccines are still effective after six months.</p>\n<p>There is evidence that Moderna's vaccine, mRNA-1273, is also potent against newer variants of the SARS-CoV-2 virus that causes the disease, including the delta variant that is now responsible for over 80% of new cases in the U.S. One could conclude from these facts that Moderna won't benefit a whole lot more from mRNA-1273. After all, the company's shares have already skyrocketed, and with the number of vaccinated people rising, how much can the biotech continue to profit from its success in this market?</p>\n<p>However, there are good reasons to think Moderna's coronavirus vaccine-related tailwind isn't over. <a href=\"https://laohu8.com/S/FBNC\">First</a>, Moderna continues to seek (and earn) regulatory wins, both in the U.S. and abroad. Back in June, the company applied for an Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for its vaccine to be administered to adolescents between the ages of 12 and 18. Moderna submitted a similar application to regulatory authorities in Switzerland last month, and the company's vaccine recently earned an EUA in India.</p>\n<p><img src=\"https://static.tigerbbs.com/6745743754cc8a567a6c76661e415ed8\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<p>Second, the biotech continues to sign new supply deals for mRNA-1273. Moderna announced a supply agreement with the government of Argentina on June 12 for 20 million doses of mRNA-1273, while both the U.S. government and the European Commission have purchased millions of additional doses of the vaccine.</p>\n<p>Finally, and perhaps most importantly, it still isn't clear how long mRNA-1273 provides immunity. During Moderna's first-quarter earnings conference call, CEO Stéphane Bancel said: \"we believe booster shots will be needed as we believe that the virus is not going away. We also believe from the scientific standpoint, that the highest efficacy booster over time will be provided by multivalent variant-specific booster.\"</p>\n<p>Moderna started evaluating booster candidates for its vaccine earlier this year. Meanwhile, Pfizer's CEO Albert Bourla has said that he believes demand for COVID-19 vaccines could become seasonal, much like the demand for flu vaccines. Of course, none of this is set in stone. The CDC and the FDA released a joint statement on July 8 saying that vaccinated Americans do not need booster shots right now.</p>\n<p>That may be true at the moment, but data from Pfizer has already strongly suggested that a booster dose administered six months post-vaccination produces higher antibodies titers in patients. This is important -- while Pfizer's vaccine remains effective after six months, its efficacy does seem to decrease.</p>\n<p>And with new variants like delta emerging, there are good reasons to think that a booster dose will eventually be needed for vaccinated people. Given these factors, it seems highly likely that Moderna will continue to benefit from its coronavirus vaccine financially, and its shares could still experience significant upside as a result.</p>\n<h3>What else does Moderna have to offer?</h3>\n<p>Beyond COVID-19, Moderna's mRNA vaccine platform shows huge potential. The company's pipeline currently boasts more than a dozen programs, most of which are potential vaccines against various infectious illnesses. In early July, the biotech started a phase 1/2 clinical trial for mRNA-1010, an investigational flu vaccine.</p>\n<p>The company argues that despite the wide availability of approved vaccines for the flu, this disease continues to cause serious health problems, in part because current vaccines are only 40% to 60% effective. Moderna is also looking to develop combination vaccines -- that is, vaccines that can confer immunity against more than <a href=\"https://laohu8.com/S/AONE.U\">one</a> disease.</p>\n<p>There is no doubt the long-term opportunity is there for the company. As Moderna argues, of the more than 80 viruses discovered in the past 40 years, only 4% have commercially available vaccines in the U.S. The company thinks its mRNA approach to vaccination could help it create a raft of effective vaccines against some of these viruses.</p>\n<h3>Not too late to get in</h3>\n<p>There are two important reasons why it's not too late to buy shares of Moderna. <a href=\"https://laohu8.com/S/FFBC\">First</a>, the company will continue to benefit from its COVID-19 vaccine. Second, the biotech's long-term thesis (supported by the success of mRNA-1273) is attractive. Moderna is currently trading at just 12.5 times forward earnings, which, in my view, is more than fair given the company's prospects. <a href=\"https://laohu8.com/S/ISBC\">Investors</a> looking for solid biotech stocks to buy need look no further than Moderna.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Too Late to Buy Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Too Late to Buy Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 21:01 GMT+8 <a href=https://www.fool.com/investing/2021/07/23/is-it-too-late-to-buy-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you had invested $100,000 in Moderna, Inc. in early 2020, you would have well over $1,500,000 today, as shares of the biotech have skyrocketed thanks to its successful development of a vaccine for ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/23/is-it-too-late-to-buy-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/07/23/is-it-too-late-to-buy-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153983451","content_text":"If you had invested $100,000 in Moderna, Inc. in early 2020, you would have well over $1,500,000 today, as shares of the biotech have skyrocketed thanks to its successful development of a vaccine for COVID-19. Any investor would be proud of such returns, particularly given the relatively short period it took the vaccine maker to accomplish this feat.\nBut that raises an interesting question: After crushing the broader market over the past year and a half, how much upside does Moderna have left? Is it too late to get in on this high-flying biotech? Let's look into Moderna's prospects, both within the coronavirus market and beyond, to determine whether it is still worth purchasing its shares.\n\n^SPX data by YCharts\nIs the coronavirus vaccine tailwind over?\nAccording to the U.S. Centers for Disease Control and Prevention (CDC), as of July 21, 161.9 million people in the U.S. have been fully vaccinated against COVID-19. Many more have received vaccines elsewhere in the world. The two leaders in this space -- Moderna and Pfizer -- have both reported that their respective vaccines are still effective after six months.\nThere is evidence that Moderna's vaccine, mRNA-1273, is also potent against newer variants of the SARS-CoV-2 virus that causes the disease, including the delta variant that is now responsible for over 80% of new cases in the U.S. One could conclude from these facts that Moderna won't benefit a whole lot more from mRNA-1273. After all, the company's shares have already skyrocketed, and with the number of vaccinated people rising, how much can the biotech continue to profit from its success in this market?\nHowever, there are good reasons to think Moderna's coronavirus vaccine-related tailwind isn't over. First, Moderna continues to seek (and earn) regulatory wins, both in the U.S. and abroad. Back in June, the company applied for an Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for its vaccine to be administered to adolescents between the ages of 12 and 18. Moderna submitted a similar application to regulatory authorities in Switzerland last month, and the company's vaccine recently earned an EUA in India.\n\nImage source: Getty Images.\nSecond, the biotech continues to sign new supply deals for mRNA-1273. Moderna announced a supply agreement with the government of Argentina on June 12 for 20 million doses of mRNA-1273, while both the U.S. government and the European Commission have purchased millions of additional doses of the vaccine.\nFinally, and perhaps most importantly, it still isn't clear how long mRNA-1273 provides immunity. During Moderna's first-quarter earnings conference call, CEO Stéphane Bancel said: \"we believe booster shots will be needed as we believe that the virus is not going away. We also believe from the scientific standpoint, that the highest efficacy booster over time will be provided by multivalent variant-specific booster.\"\nModerna started evaluating booster candidates for its vaccine earlier this year. Meanwhile, Pfizer's CEO Albert Bourla has said that he believes demand for COVID-19 vaccines could become seasonal, much like the demand for flu vaccines. Of course, none of this is set in stone. The CDC and the FDA released a joint statement on July 8 saying that vaccinated Americans do not need booster shots right now.\nThat may be true at the moment, but data from Pfizer has already strongly suggested that a booster dose administered six months post-vaccination produces higher antibodies titers in patients. This is important -- while Pfizer's vaccine remains effective after six months, its efficacy does seem to decrease.\nAnd with new variants like delta emerging, there are good reasons to think that a booster dose will eventually be needed for vaccinated people. Given these factors, it seems highly likely that Moderna will continue to benefit from its coronavirus vaccine financially, and its shares could still experience significant upside as a result.\nWhat else does Moderna have to offer?\nBeyond COVID-19, Moderna's mRNA vaccine platform shows huge potential. The company's pipeline currently boasts more than a dozen programs, most of which are potential vaccines against various infectious illnesses. In early July, the biotech started a phase 1/2 clinical trial for mRNA-1010, an investigational flu vaccine.\nThe company argues that despite the wide availability of approved vaccines for the flu, this disease continues to cause serious health problems, in part because current vaccines are only 40% to 60% effective. Moderna is also looking to develop combination vaccines -- that is, vaccines that can confer immunity against more than one disease.\nThere is no doubt the long-term opportunity is there for the company. As Moderna argues, of the more than 80 viruses discovered in the past 40 years, only 4% have commercially available vaccines in the U.S. The company thinks its mRNA approach to vaccination could help it create a raft of effective vaccines against some of these viruses.\nNot too late to get in\nThere are two important reasons why it's not too late to buy shares of Moderna. First, the company will continue to benefit from its COVID-19 vaccine. Second, the biotech's long-term thesis (supported by the success of mRNA-1273) is attractive. Moderna is currently trading at just 12.5 times forward earnings, which, in my view, is more than fair given the company's prospects. Investors looking for solid biotech stocks to buy need look no further than Moderna.","news_type":1},"isVote":1,"tweetType":1,"viewCount":243,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
